118 related articles for article (PubMed ID: 10771678)
1. [Histone deacetylase inhibitors--new anticancer agents?].
Yoshida M; Horinouchi S
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1090-5. PubMed ID: 10771678
[No Abstract] [Full Text] [Related]
2. [Biological diversity of protein lysine acetylation which has been revealed by small molecule inhibitors].
Shimazu T; Horinouchi S; Yoshida M
Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1751-7. PubMed ID: 18051411
[No Abstract] [Full Text] [Related]
3. [Epigenetics in hematological disorders].
Furukawa Y
Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
[No Abstract] [Full Text] [Related]
4. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
Richon VM; O'Brien JP
Clin Cancer Res; 2002 Mar; 8(3):662-4. PubMed ID: 11895892
[No Abstract] [Full Text] [Related]
5. [A new target of cancer therapy: advances in the study of histone deacetylase].
Liu AL; Long J; Wang N; Du GH
Yao Xue Xue Bao; 2005 Jul; 40(7):585-90. PubMed ID: 16196262
[No Abstract] [Full Text] [Related]
6. [The complexes for histone acetyltransferase and histone deacetylase].
Suka N
Tanpakushitsu Kakusan Koso; 1999 Sep; 44(12 Suppl):1788-95. PubMed ID: 10503015
[No Abstract] [Full Text] [Related]
7. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
8. [Structure and function of chromatin centered on histone acetyltransferase and histone deacetylase].
Horikoshi M
Tanpakushitsu Kakusan Koso; 2000 Jun; 45(9 Suppl):1446-64. PubMed ID: 10879121
[No Abstract] [Full Text] [Related]
9. Inhibitors of histone deacetylase are potentially effective anticancer agents.
Marks PA; Rifkind RA; Richon VM; Breslow R
Clin Cancer Res; 2001 Apr; 7(4):759-60. PubMed ID: 11309319
[No Abstract] [Full Text] [Related]
10. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
Weidle UH; Grossmann A
Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors.
Marks PA; Richon VM; Miller T; Kelly WK
Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand.
Nishino N; Yoshikawa D; Watanabe LA; Kato T; Jose B; Komatsu Y; Sumida Y; Yoshida M
Bioorg Med Chem Lett; 2004 May; 14(10):2427-31. PubMed ID: 15109626
[TBL] [Abstract][Full Text] [Related]
13. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
[TBL] [Abstract][Full Text] [Related]
14. Acetylation of non-histone proteins modulates cellular signalling at multiple levels.
Spange S; Wagner T; Heinzel T; Krämer OH
Int J Biochem Cell Biol; 2009 Jan; 41(1):185-98. PubMed ID: 18804549
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of a potent histone deacetylase inhibitor.
Liu T; Kapustin G; Etzkorn FA
J Med Chem; 2007 May; 50(9):2003-6. PubMed ID: 17419603
[TBL] [Abstract][Full Text] [Related]
16. [Structure-activity relationships of histone deacetylase inhibitors].
Tan YM; Huang WY; Yu NF
Yao Xue Xue Bao; 2009 Oct; 44(10):1072-83. PubMed ID: 20055127
[TBL] [Abstract][Full Text] [Related]
17. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
Gu W; Nusinzon I; Smith RD; Horvath CM; Silverman RB
Bioorg Med Chem; 2006 May; 14(10):3320-9. PubMed ID: 16434199
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
19. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
